GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GC Genome 340450.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

6,770

-2.03%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩31.53bn

FY2022FY2025

Net income

₩4.04bn

FY2022FY2025

Free cash flow

₩942.6m

FY2022FY2025

Shareholders' equity

₩78.27bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue₩31.53bn₩25.89bn₩27.29bn₩24.11bn
Gross profit₩14.63bn₩11.71bn₩13.70bn₩10.76bn
Research and development₩6.48bn₩6.05bn₩7.36bn₩8.12bn
Operating income₩1.24bn−₩1.23bn₩160.1m−₩2.69bn
Net income₩4.04bn−₩1.26bn−₩550.1m−₩3.76bn
Diluted earnings per share171.00-53.14-23.26-159.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets₩84.63bn₩40.62bn₩42.82bn₩48.90bn
Total liabilities₩6.35bn₩7.54bn₩17.77bn₩22.31bn
Debt—₩4.67bn₩11.76bn₩10.60bn
Shareholders' equity₩78.27bn₩33.08bn₩25.05bn₩26.59bn
Shares outstanding24m24m24m24m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations₩1.30bn₩378.0m₩3.34bn−₩1.61bn
Capital spending−₩354.4m−₩415.7m−₩7.46bn−₩4.07bn
Free cash flow₩942.6m−₩37.7m−₩4.11bn−₩5.68bn

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024
Revenue₩7.44bn₩8.08bn₩8.84bn₩7.81bn₩6.81bn₩25.89bn
Gross profit₩3.41bn₩3.84bn₩4.24bn₩3.50bn₩3.05bn₩11.71bn
Operating income₩140.0m₩200.6m₩772.7m₩287.4m−₩25.1m−₩1.23bn
Net income₩813.7m₩2.39bn₩1.43bn−₩73.0m₩296.8m−₩1.26bn
Diluted earnings per share34.40100.8960.66-3.0912.55-53.14
Cash from operations₩3.10bn−₩1.03bn₩998.0m−₩1.43bn₩2.77bn₩377.0m
Capital spending—−₩90.0m−₩126.0m−₩110.0m−₩26.0m−₩415.0m
Free cash flow—−₩1.12bn₩872.0m−₩1.54bn₩2.74bn−₩38.0m
Total assets₩88.11bn₩84.63bn₩85.48bn₩83.54bn₩42.60bn—
Shareholders' equity₩79.09bn₩78.27bn₩75.18bn₩73.74bn₩33.38bn—

Financial ratios

Data as of 5 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin46.4%45.2%50.2%44.6%
Operating margin3.9%-4.8%0.6%-11.1%
Net margin12.8%-4.9%-2.0%-15.6%
Return on equity5.2%-3.8%-2.2%-14.2%
Return on assets4.8%-3.1%-1.3%-7.7%
Revenue growth21.8%-5.1%13.2%—
Earnings growth-421.8%128.5%-85.4%—
Current ratio18.59x4.27x1.12x2.32x
Debt to equity———0.22x
Equity ratio92.5%81.4%58.5%54.4%
Interest coverage6.27x-1.29x0.17x-1.58x
R&D as a share of sales20.5%23.4%27.0%33.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.8%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin45.9%46.7%——

Valuation history

At each fiscal year end

FY2025
Price to earnings39.9
Price to sales5.2

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.